KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.

Priscilla Y Hsue, Georg M N Behrens, Zhi Jin Xu, Yujie Zhao, John Cmar, Rima Lahoulou, Rafael E Campo, Rebeca M Plank

J Acquir Immune Defic Syndr 101(2) 208-213

PMID41081774
PMCID-
DOI10.1097/QAI.0000000000003778
发表日期2025-10-13
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: People living with HIV (PLWH) on antiretroviral therapy have an increased risk of atherosclerotic cardiovascular disease (ASCVD). Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor, has a favorable lipid profile, minimal effect on weight, and is not expected to impact ASCVD risk. We evaluated the impact of DOR on ASCVD risk in PLWH in 2 phase 3 trials. SETTING: Post hoc analysis of DRIVE-FORWARD (NCT02275780) and DRIVE AHEAD (NCT02403674). METHODS: Participants were randomized to DOR + 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) or ritonavir-boosted darunavir + 2 NRTIs (DRIVE-FORWARD) or to DOR/lamivudine/tenofovir or efavirenz/emtricitabine/tenofovir (DRIVE-AHEAD) for 96 weeks. Participants could continue or switch to the DOR-based regimen in 96-week open-label extensions. The 10-year ASCVD risk was calculated at baseline and weeks 24, 48, 96, and 192. RESULTS: The 369 participants included 60.4% White men, 19.0% Black/African American men, 11.7% Black/African American women, and 8.9% White women. Baseline characteristics were generally comparable across the subgroups and trials. A slight trend toward increased ASCVD risk scores for men was observed at week 192. This increase was not observed when the analysis used age at baseline as a fixed value instead of natural age at each study visit, suggesting that age rather than DOR might have caused the increase in ASCVD risk scores in the male population. CONCLUSIONS: After ∼4 years, DOR-based regimens were not associated with changes in ASCVD risk scores in PLWH. Given the increased burden of HIV-associated ASCVD, DOR may represent a therapeutic option that does not increase ASCVD risk.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。